Genprex, Inc. 10-K — AI Bull & Bear Analysis

Genprex represents a classic high-risk, high-reward biotech play, where the potential for a breakthrough in lung cancer resistance is offset by extreme financial fragility. The 10-K reveals a company that has successfully scaled its manufacturing and streamlined its costs, yet still operates under a cloud of 'substantial doubt' regarding its ability to continue as a going concern. The upcoming 2026 interim data readouts will serve as the ultimate arbiter of value. Investors are essentially betting on the ability of the TUSC2 gene therapy to deliver repeatable, systemic efficacy across a broader cohort. If the interim analyses in H2 2026 are positive, the company may find the valuation support necessary to fund its path to a BLA. However, the current capital structure and the reliance on dilutive financing suggest that any delay or mediocre result could lead to a rapid depletion of resources and potential delisting from the Nasdaq.